Drug Type Monoclonal antibody |
Synonyms Epiregulin mAb, LY 3848575, LY3848575 |
Target |
Action inhibitors |
Mechanism EREG inhibitors(Epiregulin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuralgia | Phase 2 | United States | 22 Aug 2024 | |
Neuralgia | Phase 2 | Japan | 22 Aug 2024 | |
Neuralgia | Phase 2 | Canada | 22 Aug 2024 | |
Neuralgia | Phase 2 | Czechia | 22 Aug 2024 | |
Neuralgia | Phase 2 | Germany | 22 Aug 2024 | |
Neuralgia | Phase 2 | Mexico | 22 Aug 2024 | |
Neuralgia | Phase 2 | Poland | 22 Aug 2024 | |
Sensory polyneuropathy | Phase 2 | United States | 22 Aug 2024 | |
Sensory polyneuropathy | Phase 2 | Japan | 22 Aug 2024 | |
Sensory polyneuropathy | Phase 2 | Canada | 22 Aug 2024 |